drugset / Trial / NCT06844799
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2027-03-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20137 | Monoclonal antibody | 200 mg | Other |